Acute Leukemia Perspective

 
 
  • Top News From ASH 2016: Slideshow Practice-changing research in lymphoma and leukemia, plus growing excitement over two chimeric antigen receptor (CAR) T cell products, featured prominently at this year's meeting.
  • At ASH, New Approaches Suggest 'Major Advances' Against AML   After years of little progress, a number of new drug classes show promise for patients with AML.
  • ASH16 Preview: New CAR T-cell Data Come at a Pivotal Moment Dr Miguel-Angel Perales summarizes key recent developments in the field of CAR T cells and outlines the most important CAR T cell trials to follow at the 2016 ASH Annual Meeting.
  • American Society of Hematology (ASH) 2016 Annual Meeting Read clinically focused news coverage of key developments from ASH 2016.
  • 'Onco-lore': Diet, Social Restrictions Don't Prevent Infections   Dr Mark Kris explains how a new study upends long-held notions about the efficacy of common anti-infective measures.
  • Cancer Moonshot: We Have Liftoff Initial reaction to the Moonshot ranged from cynicism to guarded optimism, but no one denies that momentum is building for this national cancer initiative -- and Big Data are the rocket boosters.
  • What's Hot in Hematologic Malignancies   Dr Bruce Cheson gives a sneak preview of the presentations in hematologic malignancies at ASCO 2016, with a look at new agents, refined combinations, and strategies to reduce toxicities.
  • Acute Leukemia Takeaways From ASH 2015: New Agents   Dr Farhad Ravandi provides an overview of the highlights in acute myeloid leukemia and acute lymphoblastic leukemia from the 2015 American Society of Hematology Annual Meeting.
  • American Society of Hematology (ASH) 57th Annual Meeting Read clinically focused news coverage of key developments from ASHP 2015.
  • ASHCAR T-Cell Therapy at ASH 2015: What's Hot A preview of the most important research on CAR T-cell therapy at the ASH 2015 annual meeting.
  • Docetaxel in Prostate Cancer -- The Pendulum Swings Back Upfront use of docetaxel for prostate cancer has waxed and waned over the years, but recent studies have brought the agent back to the forefront.
  • What to Expect in Hematologic Malignancies   Dr Bruce Cheson previews the most important trials being presented at ASCO 2015 on Hodgkin's and non-Hodgkin's lymphoma, acute and chronic leukemia, and multiple myeloma.
  • 'Emperor' in Close-Up: A Talk With the Director   Dr Harold Burstein gets an oncologist's behind-the- cameras view of 'Cancer: The Emperor of All Maladies,' from Barak Goodman, director of the Ken Burns documentary.
  • Today's Cancer Research Pioneers More than 50 years after the introduction of chemotherapy, a new wave of researchers seek to radically advance cancer treatments.
  • Perils and Pluses of 'Compassionate Use'   When a person is dying, there may be lots of pressure to give access to drugs still in development. This happened during the recent Ebola outbreak. But there are serious pros and cons to doing this.
  • Telling Stories: Why I Went Into Oncology An oncology fellow at Duke University describes why she chose the field and discusses whether the reality lives up to her expectations.
  • The Year in Hematologic Malignancies Experts in hematologic malignancies comment on the most important developments and practice-changing clinical trials of 2014.
  • Have We Overlooked Palliative Care?   Palliative care is not just for patients in hospice, explains Dr. Diane Meier; good palliative care can help relieve the suffering of people with chronic or disabling illnesses.
  • CAR T Cells: A Look Under the Hood and Down the Road Lost your way in immunotherapy? Dr. Mark Adler provides clinicians a roadmap for navigating cancer immunotherapy and takes one of the most promising approaches -- CAR T cells -- for a test drive.
  • ASCO President on the Triumph of the Open Mind   Dr. James Holland, president of ASCO in 1976-1977, talks to Dr. Kathy Miller about the early days of oncology, the society, and the humanist passion that is a driving force for both.